News and Announcements
BitCar announces launch of test network for exotic car ownership
- Published April 25, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights
- BitCar has announced a new test network for its members to experiment with buying and trading fractional ownership of exotic, rare, super and classic cars.
- BitCar has allowed for exotic car ownership via tokenization, decentralization and peer-to-peer blockchain technology available 24/7.
- Bitcar is running a bug bounty programme whereby the discovery of any serious bugs will lead to potential reward.
BitCar has announced a new test network for its members to experiment with buying and trading fractional ownership of exotic, rare, super and classic cars. They have now launched a Minimum Viable Product version of the Ethereum Ropsten Test Net and are seeking feedback from the community in the lead up to the Main Net Launch scheduled for late April 2019.
BitCar utilises the dual token structure, whereby the BitCar’s (CAR) token is a record of the fractional ownership. In essence, the token is a digital receipt and a real-world asset-backed ‘Stablecoin’. Never before has exotic car ownership been available via tokenization, decentralization and peer-to-peer blockchain technology. Minimum participation is $USD50 with peer-to-peer trading available 24/7. Bitcar is running a bug bounty programme whereby the discovery of any serious bugs will lead to potential reward.
About BitCar
In a world first, the BitCar platform allows fractionalized ownership and decentralized peer-to-peer trading in Exotic Cars with a new BITCAR token. Imagine being a part-owner of a Ferrari F40, Maserati MC12 or Bugatti Veyron just to name a few. Owners can peg their crypto to these hard assets for protection during times of high crypto volatility.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
